卡拉生物Q3每股收益$（1.07）优于$（1.45）预期

Kala Bio (NASDAQ: KALA) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.45) by 25.95 percent. This is a 44.56 percent increase over losses of $(1.93) per share from the same period last year.